Dyne Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 141
- Market Cap
- $4.4B
- Website
- http://www.dyne-tx.com
- Introduction
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Drug: DYNE-251Drug: Placebo
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Dyne Therapeutics
- Target Recruit Count
- 88
- Registration Number
- NCT05524883
- Locations
- 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸UCLA, Los Angeles, California, United States
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
- Conditions
- Myotonic Dystrophy Type 1 (DM1)
- Interventions
- Drug: DYNE-101Drug: Placebo
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Dyne Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT05481879
- Locations
- 🇮🇹
Centro Clinico Nemo, Milan, Italy
🇫🇷Institut de Myologie, Paris, France
🇩🇪Ludwig Maximilians University, Munich - Friedrich Baur Institut, Munich, Germany